Just Health PR has been appointed by US bioscience company Caris Life Sciences to help introduce their tumour profiling technology to European markets.
Caris’ molecular intelligence (MI) service provides oncologists with clinically actionable, individualised treatment information for solid tumours.
Using a combination of technologies, including next-generation sequencing (NGS), Caris sifts a database of peer-review and published cancer research papers, in order to correlate specific biomarkers to positive drug responses.
By comparing the genetic and molecular makeup unique to each patient’s tumour with data from existing clinical studies, GPs can determine the course of treatment likely to be most effective for the individual patient.
Leading the Just Health PR push will be the agency’s head of political relations, Jon Spiers, who said: “This is an incredibly fast-moving and innovative area of medicine which is of great interest to politicians and policymakers.
“We are thrilled to be working on a technology, which has the potential to revolutionise the way we treat cancer.”
Because MI is neither a treatment nor a diagnostic, there is no clear measure for assessing its utility within the NHS. However, the Just team has begun talks with the Department of Health, the Technology Strategy Board, the NHS Technology Adoption Centre and the Downing Street Policy Unit to determine how the health service might adopt the technology.